Paper Details

  1. Home
  2. Paper Details

Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.

Author: BratinaAlessio, CheliMarta, DinotoAlessandro, ManganottiPaolo, SartoriArianna

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Bortezomib, a proteasome inhibitor, has a promising role in treating N-methyl-d-aspartate receptor (NMDAR) encephalitis, a potentially treatable condition. A literature review found that bortezomib improved outcomes in 55.2% of patients but caused side effects in 37.9%.
Paper Details　
Original Abstract of the Article :
N-methyl-d-aspartate receptor (NMDAR) encephalitis is a potentially treatable condition, although a small proportion of patients remains refractory to immunotherapy. Bortezomib is a proteasome inhibitor that has a promising role in autoimmune conditions. We performed an independent PubMed search emp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jneuroim.2021.577586

データ提供：米国国立医学図書館（NLM）

Bortezomib: A Potential Treatment for Anti-NMDA Receptor Encephalitis

Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is a rare but serious autoimmune disorder that can lead to severe neurological complications. This study reviews the existing literature on the use of bortezomib, a proteasome inhibitor, in patients with anti-NMDAR encephalitis. The study aims to assess the efficacy and safety of bortezomib as a treatment option for this challenging condition.

Bortezomib: A Potential Treatment for Refractory Anti-NMDAR Encephalitis

The study's findings suggest that bortezomib may be a promising treatment option for patients with anti-NMDAR encephalitis who are refractory to conventional immunotherapy. The study highlights the need for further research to validate these findings and to develop evidence-based guidelines for the use of bortezomib in this population.

Navigating the Desert of Neurological Complications: A Search for New Therapies

Imagine a desert traveler facing a treacherous landscape of neurological complications, seeking a path to recovery. Anti-NMDAR encephalitis is like that, a complex and debilitating condition. This study's findings offer a glimmer of hope for patients seeking effective treatment options, exploring the potential of bortezomib to provide relief from the debilitating effects of this disorder.

Dr.Camel's Conclusion

The study's findings provide valuable insights into the potential of bortezomib as a treatment option for anti-NMDAR encephalitis. It highlights the need for continued research to understand the mechanisms of action of this medication and to determine its optimal role in the management of this complex neurological disorder.

Date :
  1. Date Completed 2021-09-07
  2. Date Revised 2021-09-07
Further Info :

Pubmed ID

33975246

DOI: Digital Object Identifier

10.1016/j.jneuroim.2021.577586

Related Literature

Article Analysis
・Side Effects of bortezomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.